Yogesh Punekar

Dolutegravir versus ritonavir-boosted lopinavir both with dual nucleoside reverse transcriptase inhibitor therapy in adults with HIV-1 infection in whom first-line therapy has failed (DAWNING): an open-label, non-inferiority, phase 3b trial

Michael Aboud, Richard Kaplan, Johannes Lombaard et al. · The Lancet Infectious Diseases · 2019 · 198 citations

Pharmacy, Infectious Diseases, Pharmacotherapy +12

Continuing to Confront COPD International Patient Survey: Economic Impact of COPD in 12 Countries

Jason Foo, Sarah Landis, Joe Maskell et al. · PLoS ONE · 2016 · 166 citations · Full text

Medicine, Health Sciences, Internal Medicine +17

COPD management costs according to the frequency of COPD exacerbations in UK primary care

Yogesh Punekar, Amit Shukla, Hana Müllerová · International Journal of COPD · 2014 · 108 citations · Full text

Medicine, Clinical Sciences, Internal Medicine +16

Health‐economic analysis: cost‐effectiveness of scheduled maintenance treatment with infliximab for Crohn’s disease – modelling outcomes in active luminal and fistulizing disease in adults

James O. Lindsay, Yogesh Punekar, Jonathan Morris et al. · Alimentary Pharmacology & Therapeutics · 2008 · 79 citations · Full text

Pharmacy, Pharmacoeconomics, Pharmacotherapy +17

Prevalence, determinants, and impact of suboptimal adherence to HIV medication in 25 countries

Patricia Rios, Chinyere Okoli, Yogesh Punekar et al. · Preventive Medicine · 2020 · 76 citations · Full text

Public Health, Health Sciences, Health Services Research +16